Immuneering Corporation

NasdaqGM IMRX

Immuneering Corporation EBIT Margin for the Trailing 12 Months (TTM) ending September 30, 2024

Immuneering Corporation EBIT Margin is NA for the Trailing 12 Months (TTM) ending September 30, 2024. EBIT ratio is the ratio of EBIT to revenue, measuring a company's operating profitability without considering non-operating income or expenses.

Immuneering Corporation EBIT Margin for the Trailing 12 Months (TTM) ending September 30, 2022 was -9,700.30%.

Key data

Date	EBIT Margin	EPS (Basic)	EPS (Diluted)	Shares (Basic, Weighted)

NasdaqGM: IMRX

Immuneering Corporation

CEO	Dr. Benjamin J. Zeskind M.B.A., Ph.D.
IPO Date	July 30, 2021
Location	United States
Headquarters	245 Main Street
Employees	66
Sector	Healthcare
Industries Biotechnology Clinical Trials Pharmaceuticals

Description

Immuneering Corporation, a biopharmaceutical company, focuses on the oncology and neuroscience product candidates. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 to treat solid tumors. The company also has five oncology programs in the discovery stage that are designed to target components of the MAPK or mTOR pathway; and two discovery stage neuroscience programs. Immuneering Corporation was incorporated in 2008 and is based in Cambridge, Massachusetts. Immuneering Corporation was a former subsidiary of Teva Pharmaceutical Industries Limited.

Key trends

Past 5 years